Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Danazol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR known ✓ | P06401 | 3/20 | 1.00 |
| ▸ | AR known ✓ | P10275 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 5/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SHBG | P04278 | 4/20 | 1.00 |
| ▸ | ESR1 | P03372 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danazol SCHEMBL14045163 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL5021653 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL21107 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL13184574 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL7722243 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL23468175 | 1.00 | CYP3A4 (1.00) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL5248054 | 0.99 | CYP3A4 (0.98) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL27720831 | 0.96 | CYP3A4 (0.93) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL4780325 | 0.93 | LMNA (0.86) | CYP3A4LMNATSHRCYP2C19HIF1A | |
| Danazol SCHEMBL3146698 | 0.89 | CYP3A4 (0.80) | CYP3A4LMNATSHRCYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-101528196-A | Self-emulsifying compositions for poorly bioavailable drugs | HOVID BERHAD (MY) | 2009-09-09 | — | — | CN | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-1305029-A4 | METHOD OF INCREASING SENSITIVITY OF MAMMOGRAPHY | CLEVELAND CLINIC FOUNDATION (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-1305029-A1 | METHOD OF INCREASING SENSITIVITY OF MAMMOGRAPHY | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002009721-A1 | METHOD OF INCREASING SENSITIVITY OF MAMMOGRAPHY | THE CLEVELAND CLINIC FOUNDATION (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-0929295-A4 | — | — | 1999-08-18 | — | — | EP | disclosed |
| EP-0929295-A1 | COMBINED PHARMACEUTICAL ESTROGEN-ANDROGEN-PROGESTIN ORAL CONTRACEPTIVE | WAKE FOREST UNIVERSITY (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998001115-A1 | COMBINED PHARMACEUTICAL ESTROGEN-ANDROGEN-PROGESTIN ORAL CONTRACEPTIVE | WAKE FOREST UNIVERSITY (US) | 1998-01-15 | — | — | WO | disclosed |
| US-4837212-A | Treatment of hemolytic anemia with danazol | UNIVERSITY OF MIAMI (US) | 1989-06-06 | — | — | US | disclosed |